Skip to search formSkip to main contentSkip to account menu

perampanel

Known as: Benzonitrile, 2-(1',6'-Dihydro-6'-oxo-1'-phenyl(2,3'-bipyridin)-5'-yl)-, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, Perampanelum 
An orally active, non-competitive, and selective alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist, with… 
National Institutes of Health

Related topics

Related topics

7 relations
AMPA Receptor Antagonists [MoA]perampanel 0.5 MG/ML Oral Suspensionperampanel 10 MG Oral Tabletperampanel 6 MG Oral Tablet

Narrower (1)

FYCOMPA

Broader (1)

Pyridones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Mechanisms of action of currently used antiseizure drugs
Highly Cited
2015
Highly Cited
2015
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy
Objective: To assess efficacy and safety of adjunctive perampanel in patients with drug-resistant, primary generalized tonic… 
Review
2015
Review
2015
The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist
The clinical pharmacology profile of a drug critically determines its therapeutics, and this review summarizes the… 
Review
2015
Review
2015
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Review
2013
Review
2013
Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist
Perampanel [2‐(2‐oxo‐1‐phenyl‐5‐pyridin‐2‐yl‐1,2‐dihydropyridin‐3‐yl)benzonitrile; E2007] is a potent, selective, orally active… 
Highly Cited
2013
Highly Cited
2013
Concentration–effect relationships with perampanel in patients with pharmacoresistant partial‐onset seizures
Although there is a general paucity of published pharmacokinetic (PK) data for new antiepileptic drugs (AEDs), PK analyses of… 
Highly Cited
2013
Highly Cited
2013
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies
Three phase III studies (304 [ClinicalTrials.gov identifier: NCT00699972], 305 [NCT00699582], 306 [NCT00700310]) evaluated… 
Highly Cited
2012
Highly Cited
2012
Adjunctive perampanel for refractory partial-onset seizures
Objective: To evaluate the efficacy and safety of perampanel 2, 4, and 8 mg/day added to 1–3 concomitant antiepileptic drugs… 
Highly Cited
2011
Highly Cited
2011
Perampanel: A novel, orally active, noncompetitive AMPA‐receptor antagonist that reduces seizure activity in rodent models of epilepsy
Purpose:  To assess the pharmacology of perampanel and its antiseizure activity in preclinical models. Perampanel [2‐(2‐oxo‐1… 
Highly Cited
2009
Highly Cited
2009
In vitro and in vivo evaluation of the surface bioactivity of a calcium phosphate coated magnesium alloy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)